Developer docs
API playgroundTry for free, no card

Search company profiles

AIMM Therapeutics

Full company profile

uuid000bl7m

Namestring
AIMM Therapeutics
Legal namestring
Kling Biotherapeutics BV
Company typeenum
Private
Founded yearint
2004
Descriptiontext

AIMM Therapeutics, now operating as Kling Biotherapeutics BV, is a clinical-stage privately held biotechnology company headquartered in Amsterdam, the Netherlands. The company develops antibody-based therapeutics through a proprietary patient-derived B cell discovery platform, designed to identify novel therapeutic targets and corresponding human antibody binders directly from patients exhibiting exceptional clinical responses. Its core offering centers on two fully owned platform technologies: Kling-Select, a clinically validated B cell immortalization method that enables simultaneous discovery of novel targets and fully human antibodies (notably credited with the discovery of nirsevimab/Beyfortus, a marketed RSV antibody estimated to be a billion-dollar-plus product, plus neutralizing antibodies for Covid and Influenza); and Kling-Evolve, an ex vivo affinity maturation technology used to evolve B cell clones for affinity/selectivity improvement or rapid response to emerging viral variants.

Kling Biotherapeutics is progressing an internal oncology pipeline led by KBA1412, a first-in-class CD9 antibody currently in a Phase 1 clinical trial. Additional pipeline assets have emerged from applying Kling-Select to peripheral and tumor-infiltrating B cells from cancer patients, generating a portfolio of novel and selective target-antibody pairs. The company operates as a pre-commercial R&D organization with no disclosed product revenue, monetizing through licensing and partnership economics at the platform or asset level (no pricing or revenue mechanics are publicly disclosed). It is led by Tim Wright (Chairman, General Partner at Time BioVentures), D.A. Wallach (Director, Time BioVentures) and CSO Stefano Gulla, with implied venture backing from Time BioVentures. The company serves pharmaceutical partners, healthcare providers, and ultimately patients in oncology and infectious disease indications across the EMEA market.

Short descriptiontext

Kling Biotherapeutics (formerly AIMM Therapeutics) is a clinical-stage Amsterdam biotech that discovers antibody therapeutics from patient-derived B cells using its proprietary Kling-Select and Kling-Evolve platforms, with lead asset KBA1412 (anti-CD9) in Phase 1 oncology trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAmsterdam, Netherlands
HQ citystring
Amsterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody discovery, B cell immortalization, antibody therapeutics development, oncology pipeline programs, clinical-stage biotechnology
Industry1 code
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals / Antibody Therapeutics Discovery
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Kling-Select
Description

Fully-owned and clinically-validated B cell immortalization technology to identify novel therapeutic targets and antibody binders from patients with exceptional clinical responses.

klingbio.com
+1 more record
Core offering1 text field

AIMM Therapeutics (operating as Kling Biotherapeutics) develops antibody-based therapeutics using its proprietary B cell immortalization platform, Kling-Select, which enables the simultaneous discovery of novel therapeutic targets and identification of fully human antibodies from patient-derived B cells. Its second platform, Kling-Evolve, performs ex vivo affinity maturation to optimize antibody affinity, selectivity, and responsiveness to emerging viral variants. The company applies these platforms to build and progress an internal pipeline of oncology and infectious disease antibody programs, including lead candidate KBA1412, a first-in-class CD9 antibody currently in Phase 1 clinical trials.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Kling Biotherapeutics is a clinical-stage privately held biotech company offering a unified platform approach for antibody-based therapeutic discovery. The company's core offering consists of two proprietary platform technologies: Kling-Select (B cell immortalization for simultaneous target and antibody discovery) and Kling-Evolve (ex vivo affinity maturation for antibody optimization). These platforms work together to enable unbiased identification of novel therapeutic targets and unique epitopes inaccessible to traditional approaches. The company is progressing a pipeline of oncology programs led by KBA1412, a first-in-class CD9 antibody in Phase 1 clinical trials.

Product and service3 records
1Kling-Select
Categoryplatform technology
Description

Fully-owned and clinically-validated B cell immortalization technology enabling simultaneous discovery of novel therapeutic targets and identification of fully human antibody binders from patient-derived B cells, with demonstrated applications in oncology and infectious disease (RSV, Covid, Influenza). Intended for biopharma partners seeking differentiated antibody candidates and targets.

2Kling-Evolve
Categoryplatform technology
Description

Ex vivo affinity maturation technology that enables rapid evolution of B cell clones against targets of interest, used to engineer neutralizing antibodies against emerging viral variants and to improve affinity and selectivity of oncology antibody assets. Intended for biopharma partners and internal pipeline optimization.

3KBA1412
Categorypipeline product
Description

First-in-class CD9 antibody and the company's lead clinical oncology asset, currently being evaluated in a Phase 1 clinical trial. Aimed at oncology indications where CD9-targeted therapy represents a novel mechanism.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

MacroGenics develops antibody-based therapeutics including bispecifics, with proprietary DART platform. Comparable as a clinical-stage antibody platform company developing oncology biologics, similar to Kling's CD9 program.

TypeBroad incumbent
Description

Genmab is a leading commercial-stage antibody therapeutics company with proprietary platforms (e.g., DuoBody bispecifics). It is a comparable antibody-focused biotech with much greater scale, relevant for benchmarking platform-to-product translation potential.

3Harbour BioMed
TypeEmerging player
Description

Harbour BioMed is a clinical-stage antibody therapeutics company with discovery platforms (e.g., H2L2, HCAb) generating novel antibodies. Comparable as a platform-driven, clinical-stage antibody company with proprietary discovery technology.

TypeBroad incumbent
Description

AstraZeneca is the developer and commercializer of nirsevimab/Beyfortus, the antibody originally discovered using Kling's B cell platform. AZ represents the most direct validation of Kling's historical technology output.

5Atreca
TypeDirect peer
Description

Atreca develops antibody therapeutics using immune response interrogation of patients, similar to Kling's B cell-based discovery. Both companies use patient-derived samples to identify novel targets and antibody binders, making them directly comparable platform peers.

TypeDirect peer
Description

Adimab operates a proprietary antibody discovery and optimization platform serving pharma partners. While yeast-based rather than B cell-based, both companies compete in the differentiated antibody discovery space with platform-based licensing business models.

TypeBroad incumbent
Description

Regeneron is a major antibody therapeutics company with its own B cell and VelocImmune platforms. It represents a direct benchmark for what a fully-integrated, successful antibody-discovery platform can achieve commercially.

8Distributed Bio
TypeOthers
Description

Distributed Bio (acquired by Charles River) provides antibody discovery and engineering services including B cell screening. Comparable as an adjacent, platform-oriented antibody discovery services provider in the broader ecosystem.

9Arsanis
TypeEmerging player
Description

Arsanis (and successor entities) focused on monoclonal antibody therapeutics for infectious diseases, including RSV. This is a partially overlapping peer in the infectious-disease antibody space where Kling has demonstrated capability.

TypeRegional player
Description

Merus is a Netherlands-based clinical-stage biotech developing bispecific and other therapeutic antibodies. Its Dutch HQ and clinical-stage antibody focus make it a strong regional comparison for Kling Biotherapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AIMM Therapeutics

Biopharmaceuticals / Antibody Therapeutics Discoveryaimmtherapeutics.com

Kling Biotherapeutics (formerly AIMM Therapeutics) is a clinical-stage Amsterdam biotech that discovers antibody therapeutics from patient-derived B cells using its proprietary Kling-Select and Kling-Evolve platforms, with lead asset KBA1412 (anti-CD9) in Phase 1 oncology trials.

What AIMM Therapeutics does

AIMM Therapeutics, now operating as Kling Biotherapeutics BV, is a clinical-stage privately held biotechnology company headquartered in Amsterdam, the Netherlands. The company develops antibody-based therapeutics through a proprietary patient-derived B cell discovery platform, designed to identify novel therapeutic targets and corresponding human antibody binders directly from patients exhibiting exceptional clinical responses. Its core offering centers on two fully owned platform technologies: Kling-Select, a clinically validated B cell immortalization method that enables simultaneous discovery of novel targets and fully human antibodies (notably credited with the discovery of nirsevimab/Beyfortus, a marketed RSV antibody estimated to be a billion-dollar-plus product, plus neutralizing antibodies for Covid and Influenza); and Kling-Evolve, an ex vivo affinity maturation technology used to evolve B cell clones for affinity/selectivity improvement or rapid response to emerging viral variants.

Kling Biotherapeutics is progressing an internal oncology pipeline led by KBA1412, a first-in-class CD9 antibody currently in a Phase 1 clinical trial. Additional pipeline assets have emerged from applying Kling-Select to peripheral and tumor-infiltrating B cells from cancer patients, generating a portfolio of novel and selective target-antibody pairs. The company operates as a pre-commercial R&D organization with no disclosed product revenue, monetizing through licensing and partnership economics at the platform or asset level (no pricing or revenue mechanics are publicly disclosed). It is led by Tim Wright (Chairman, General Partner at Time BioVentures), D.A. Wallach (Director, Time BioVentures) and CSO Stefano Gulla, with implied venture backing from Time BioVentures. The company serves pharmaceutical partners, healthcare providers, and ultimately patients in oncology and infectious disease indications across the EMEA market.

AIMM Therapeutics firmographics

Firmographics
Name
AIMM Therapeutics
Legal name
Kling Biotherapeutics BV
Website
https://aimmtherapeutics.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Short description
Kling Biotherapeutics (formerly AIMM Therapeutics) is a clinical-stage Amsterdam biotech that discovers antibody therapeutics from patient-derived B cells using its proprietary Kling-Select and Kling-Evolve platforms, with lead asset KBA1412 (anti-CD9) in Phase 1 oncology trials.
Ownership category
akta.pro rank

AIMM Therapeutics industry classification

Industry
Product category
Biopharmaceuticals / Antibody Therapeutics Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Monoclonal antibody discovery
  • B cell immortalization
  • Antibody therapeutics development
  • Oncology pipeline programs
  • Clinical-stage biotechnology

Where AIMM Therapeutics is headquartered

Location

Headquarters

HQ city
Amsterdam
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

AIMM Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Others

AIMM Therapeutics product offering

Product offering

Core offering

AIMM Therapeutics (operating as Kling Biotherapeutics) develops antibody-based therapeutics using its proprietary B cell immortalization platform, Kling-Select, which enables the simultaneous discovery of novel therapeutic targets and identification of fully human antibodies from patient-derived B cells. Its second platform, Kling-Evolve, performs ex vivo affinity maturation to optimize antibody affinity, selectivity, and responsiveness to emerging viral variants. The company applies these platforms to build and progress an internal pipeline of oncology and infectious disease antibody programs, including lead candidate KBA1412, a first-in-class CD9 antibody currently in Phase 1 clinical trials.

Product overview

Kling Biotherapeutics is a clinical-stage privately held biotech company offering a unified platform approach for antibody-based therapeutic discovery. The company's core offering consists of two proprietary platform technologies: Kling-Select (B cell immortalization for simultaneous target and antibody discovery) and Kling-Evolve (ex vivo affinity maturation for antibody optimization). These platforms work together to enable unbiased identification of novel therapeutic targets and unique epitopes inaccessible to traditional approaches. The company is progressing a pipeline of oncology programs led by KBA1412, a first-in-class CD9 antibody in Phase 1 clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

  • Kling-Select: Fully-owned and clinically-validated B cell immortalization technology to identify novel therapeutic targets and antibody binders from patients with exceptional clinical responses.
  • Kling-Evolve

Products and services

  • Kling-Select Fully-owned and clinically-validated B cell immortalization technology enabling simultaneous discovery of novel therapeutic targets and identification of fully human antibody binders from patient-derived B cells, with demonstrated applications in oncology and infectious disease (RSV, Covid, Influenza). Intended for biopharma partners seeking differentiated antibody candidates and targets.
  • Kling-Evolve Ex vivo affinity maturation technology that enables rapid evolution of B cell clones against targets of interest, used to engineer neutralizing antibodies against emerging viral variants and to improve affinity and selectivity of oncology antibody assets. Intended for biopharma partners and internal pipeline optimization.
  • KBA1412 First-in-class CD9 antibody and the company's lead clinical oncology asset, currently being evaluated in a Phase 1 clinical trial. Aimed at oncology indications where CD9-targeted therapy represents a novel mechanism.

Companies that use AIMM Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

AIMM Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

AIMM Therapeutics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

AIMM Therapeutics competitors and assessment

Company assessment

Emerging players

  • MacroGenics: MacroGenics develops antibody-based therapeutics including bispecifics, with proprietary DART platform. Comparable as a clinical-stage antibody platform company developing oncology biologics, similar to Kling's CD9 program.
  • Harbour BioMed: Harbour BioMed is a clinical-stage antibody therapeutics company with discovery platforms (e.g., H2L2, HCAb) generating novel antibodies. Comparable as a platform-driven, clinical-stage antibody company with proprietary discovery technology.
  • Arsanis: Arsanis (and successor entities) focused on monoclonal antibody therapeutics for infectious diseases, including RSV. This is a partially overlapping peer in the infectious-disease antibody space where Kling has demonstrated capability.

Broad incumbents

  • Genmab: Genmab is a leading commercial-stage antibody therapeutics company with proprietary platforms (e.g., DuoBody bispecifics). It is a comparable antibody-focused biotech with much greater scale, relevant for benchmarking platform-to-product translation potential.
  • AstraZeneca: AstraZeneca is the developer and commercializer of nirsevimab/Beyfortus, the antibody originally discovered using Kling's B cell platform. AZ represents the most direct validation of Kling's historical technology output.
  • Regeneron Pharmaceuticals: Regeneron is a major antibody therapeutics company with its own B cell and VelocImmune platforms. It represents a direct benchmark for what a fully-integrated, successful antibody-discovery platform can achieve commercially.

Direct peers

  • Atreca: Atreca develops antibody therapeutics using immune response interrogation of patients, similar to Kling's B cell-based discovery. Both companies use patient-derived samples to identify novel targets and antibody binders, making them directly comparable platform peers.
  • Adimab: Adimab operates a proprietary antibody discovery and optimization platform serving pharma partners. While yeast-based rather than B cell-based, both companies compete in the differentiated antibody discovery space with platform-based licensing business models.

Others

  • Distributed Bio: Distributed Bio (acquired by Charles River) provides antibody discovery and engineering services including B cell screening. Comparable as an adjacent, platform-oriented antibody discovery services provider in the broader ecosystem.

Regional players

  • Merus: Merus is a Netherlands-based clinical-stage biotech developing bispecific and other therapeutic antibodies. Its Dutch HQ and clinical-stage antibody focus make it a strong regional comparison for Kling Biotherapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

AIMM Therapeutics social profiles

Digital presence

AIMM Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AIMM Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

AIMM Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AIMM Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AIMM Therapeutics

What does AIMM Therapeutics do?

AIMM Therapeutics (operating as Kling Biotherapeutics) develops antibody-based therapeutics using its proprietary B cell immortalization platform, Kling-Select, which enables the simultaneous discovery of novel therapeutic targets and identification of fully human antibodies from patient-derived B cells. Its second platform, Kling-Evolve, performs ex vivo affinity maturation to optimize antibody affinity, selectivity, and responsiveness to emerging viral variants. The company applies these platforms to build and progress an internal pipeline of oncology and infectious disease antibody programs, including lead candidate KBA1412, a first-in-class CD9 antibody currently in Phase 1 clinical trials.

Is AIMM Therapeutics a public or private company?

AIMM Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was AIMM Therapeutics founded?

AIMM Therapeutics was founded in 2004. It employs 11 to 50 people.

Where is AIMM Therapeutics based?

AIMM Therapeutics is headquartered in Amsterdam, Netherlands, in the Europe region.

Who are AIMM Therapeutics's main competitors?

Emerging players on record are MacroGenics, Harbour BioMed and Arsanis. Broad incumbents are Genmab, AstraZeneca and Regeneron Pharmaceuticals. Direct peers are Atreca and Adimab. Distributed Bio is listed as an others. Merus is listed as a regional player.

Does AIMM Therapeutics have an API?

No public API is recorded for AIMM Therapeutics.

What industry is AIMM Therapeutics in?

AIMM Therapeutics's product category is Biopharmaceuticals / Antibody Therapeutics Discovery. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals